Current Report Filing (8-k)
May 13 2020 - 8:51AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 13, 2020
DELMAR PHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
001-37823
|
|
99-0360497
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
12707 High Bluff Dr., Suite 200
San Diego, CA 92130
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number,
including area code: (858) 350-4364
Not Applicable
|
(Former name or former address, if changed
since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
DMPI
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
DelMar Pharmaceuticals, Inc. (the “Company”) issued
a press release on May 13, 2020, disclosing financial information and operating metrics for its three month period ended March
31, 2020, and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
See “Item 2.02 Results of Operation and
Financial Condition” above.
The information in this Current Report on Form 8-K under Items 2.02
and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and
shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing
under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except as shall be expressly
set forth by a specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DELMAR PHARMACEUTICALS, INC.
|
|
|
Date: May 13, 2020
|
By:
|
/s/ Scott Praill
|
|
|
Name: Scott Praill
Title: Chief Financial Officer
|
Kintara Therapeutics (PK) (USOTC:DMPWW)
Historical Stock Chart
From May 2024 to Jun 2024
Kintara Therapeutics (PK) (USOTC:DMPWW)
Historical Stock Chart
From Jun 2023 to Jun 2024